Immune Infiltrate Analysis of Psoriasis Skin During Therapy With Anti-interleukin 23 (IL-23)

Recruiting now

Conditions studied: Psoriasis

In brief

Psoriasis is an immune-mediated inflammatory skin disease characterized by the presence of erythematous and itchy plaques. Psoriasis has a multifactorial pathogenesis, environmental and genetic factors contribute to its development. Although interleukin-23 blockade has been shown to be highly effective in the treatment of psoriasis, relapses have occurred during therapy. Our study aims to identify the cellular source of key cytokines involved in disease recurrence or persistence of at least one psoriatic lesion in patients affected by moderate- severe psoriasis treated with an anti-IL-23 biologic drug. The immune infiltrate of resistant or relapsed plaques during anti-IL-23 therapy will be analysed from skin biopsies.

Key facts

Study ID

NCT06792487

Run by

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

People needed

20

Starts

2024-09-04

Expected to finish

2027-01-01

Last updated by the study team

2025-01-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• moderate-severe psoriasis PASI>10
• anti IL 23 biologic therapy for at least 6 months (for the group under treatment)
• during therapy at least one area resistant to treatment or at least one flare of disease (for the group under treatment)
• patients able to express informed consent

You may not qualify if…

• patients unable to express informed consent
• patients with complete response to anti IL23, without resistant plaques or disease flare-ups

Where it is running

• Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC Dermatologia — Rome, Lazio, Italy (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.